Thyroid carcinoma, version 2.2018: Featured updates to the NCCN Guidelines Journal Article
| Authors: | Haddad, R. I.; Nasr, C.; Bischoff, L.; Busaidy, N. L.; Byrd, D.; Callender, G.; Dickson, P.; Duh, Q. Y.; Ehya, H.; Goldner, W.; Haymart, M.; Hoh, C.; Hunt, J. P.; Iagaru, A.; Kandeel, F.; Kopp, P.; Lamonica, D. M.; McIver, B.; Raeburn, C. D.; Ridge, J. A.; Ringel, M. D.; Scheri, R. P.; Shah, J. P.; Sippel, R.; Smallridge, R. C.; Sturgeon, C.; Wang, T. N.; Wirth, L. J.; Wong, R. J.; Johnson-Chilla, A.; Hoffmann, K. G.; Gurski, L. A. |
| Article Title: | Thyroid carcinoma, version 2.2018: Featured updates to the NCCN Guidelines |
| Abstract: | The NCCN Guidelines for Thyroid Carcinoma provide recommendations for the management of different types of thyroid carcinoma, including papillary, follicular, Hürthle cell, medullary, and anaplastic carcinomas. These NCCN Guidelines Insights summarize the panel discussion behind recent updates to the guidelines, including the expanding role of molecular testing for differentiated thyroid carcinoma, implications of the new pathologic diagnosis of noninvasive follicular thyroid neoplasm with papillary-like nuclear features, and the addition of a new targeted therapy option for BRAF V600E–mutated anaplastic thyroid carcinoma. © National Comprehensive Cancer Network, Inc. 2018, All rights reserved. |
| Journal Title: | Journal of the National Comprehensive Cancer Network |
| Volume: | 16 |
| Issue: | 12 |
| ISSN: | 1540-1405 |
| Publisher: | Harborside Press |
| Date Published: | 2018-12-01 |
| Start Page: | 1429 |
| End Page: | 1440 |
| Language: | English |
| DOI: | 10.6004/jnccn.2018.0089 |
| PROVIDER: | scopus |
| PUBMED: | 30545990 |
| DOI/URL: | |
| Notes: | JNCCN J. Nat. Compr. Cancer Netw. -- Export Date: 2 January 2019 -- Article -- Source: Scopus C2 - 30545990 |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work